Position 5-7: Finalization

Subcutaneous Tissue

Select the specific approach and device combination to identify the exact billable procedure code.

Approach 3

Percutaneous

Device 1

XW01318 Introduction Subcutaneous Tissue to New Technology Group 8 with Daratumumab and Hyaluronidase-fihj, Percutaneous Approach

Device 2

XW01329 Introduction Subcutaneous Tissue to New Technology Group 9 with Talquetamab Antineoplastic, Percutaneous Approach

Device 4

XW01348 Introduction Subcutaneous Tissue to New Technology Group 8 with Teclistamab Antineoplastic, Percutaneous Approach

Device 6

XW0136A Introduction Subcutaneous Tissue to New Technology Group 10 with Dasiglucagon, Percutaneous Approach

Device 9

XW01397 Introduction Subcutaneous Tissue to New Technology Group 7 with Satralizumab-mwge, Percutaneous Approach

Device F

XW013F5 Introduction Subcutaneous Tissue to New Technology Group 5 with Other New Technology Therapeutic Substance, Percutaneous Approach

Device G

XW013G6 Introduction Subcutaneous Tissue to New Technology Group 6 with REGN-COV2 Monoclonal Antibody, Percutaneous Approach

Device H

XW013H6 Introduction Subcutaneous Tissue to New Technology Group 6 with Other New Technology Monoclonal Antibody, Percutaneous Approach

Device K

XW013K6 Introduction Subcutaneous Tissue to New Technology Group 6 with Leronlimab Monoclonal Antibody, Percutaneous Approach

Device L

XW013L9 Introduction Subcutaneous Tissue to New Technology Group 9 with Elranatamab Antineoplastic, Percutaneous Approach

Device S

XW013S6 Introduction Subcutaneous Tissue to New Technology Group 6 with COVID-19 Vaccine Dose 1, Percutaneous Approach
XW013S9 Introduction Subcutaneous Tissue to New Technology Group 9 with Epcoritamab Monoclonal Antibody, Percutaneous Approach

Device T

XW013T6 Introduction Subcutaneous Tissue to New Technology Group 6 with COVID-19 Vaccine Dose 2, Percutaneous Approach
XW013TB Introduction Subcutaneous Tissue to New Technology Group 11 with Rozanolixizumab-noli Monoclonal Antibody, Percutaneous Approach

Device U

XW013U6 Introduction Subcutaneous Tissue to New Technology Group 6 with COVID-19 Vaccine, Percutaneous Approach

Device V

XW013V7 Introduction Subcutaneous Tissue to New Technology Group 7 with COVID-19 Vaccine Dose 3, Percutaneous Approach

Device W

XW013W5 Introduction Subcutaneous Tissue to New Technology Group 5 with Caplacizumab, Percutaneous Approach
XW013W7 Introduction Subcutaneous Tissue to New Technology Group 7 with COVID-19 Vaccine Booster, Percutaneous Approach
Approach X

External

Device 2

XW01X27 Introduction Subcutaneous Tissue to New Technology Group 7 with Anacaulase-bcdb, External Approach